TRML
Tourmaline Bio, Inc.
$47.98
+0.00
(+0.00%)
Mkt Cap
1.23B
Volume
783,730
52W Range
11.56-48.27
Sector
Healthcare
Beta
1.58
EPS (TTM)
-3.43
P/E Ratio
-7.02
Revenue (TTM)
40,000
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Tourmaline Bio, Inc. is a clinical-stage biotechnology firm committed to advancing therapies for individuals suffering from debilitating immune disorders. The company's development pipeline focuses on conditions such as Atherosclerotic Cardiovascular Disease (ASCVD) and Thyroid Eye Disease (TED). Established in 2021, this enterprise is headquartered in New York, New York.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (73.21M) | (42.12M) | (19.70M) | (904) | (22.71M) | (18.16M) |
| EPS | -2.89 | -8.87 | -0.97 | -0.00 | -33.97 | -4.39 |
| Free Cash Flow | (77.27M) | (28.14M) | (11.53M) | (42.42M) | (20.50M) | (18.22M) |
| FCF / Share | -3.05 | -5.93 | -0.57 | -3.90 | -30.66 | -4.41 |
| Operating CF | (77.26M) | (28.08M) | (6.46M) | (39.99M) | (19.21M) | (17.66M) |
| Total Assets | 309.00M | 210.29M | 9.10M | 251.42M | 152.78M | 41.94M |
| Total Debt | 244,000 | 415,000 | 504,000 | 150,000 | 0 | 0 |
| Cash & Equiv | 30.51M | 140.73M | 8.26M | 18.61M | 17.59M | 38.98M |
| Book Value | 300.05M | 205.04M | (19.73M) | 242.81M | 148.00M | 39.59M |
| Return on Equity | -0.24 | -0.21 | N/A | -0.00 | -0.15 | -0.46 |
| Metric | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 40,000 | 0 | 0 | 0 | 2.28M | 0 | 0 | 0 | 0 | 0 |
| Net Income | (23.09M) | (22.97M) | (22.23M) | (20.18M) | (17.49M) | (13.31M) | (12.90M) | (7.01M) | (16.13M) | (7.50M) | (4,920) | (1,955) |
| EPS | -0.90 | -0.89 | -0.86 | -0.78 | -0.68 | -0.55 | -0.81 | -0.34 | -1.30 | -0.37 | -0.00 | -0.00 |
| Free Cash Flow | (20.27M) | (21.69M) | (20.90M) | (23.44M) | (18.01M) | (14.92M) | 11.02M | (26.27M) | (9.55M) | (3.81M) | (2.30M) | (13.77M) |
| FCF / Share | -0.79 | -0.84 | -0.81 | -0.91 | -0.70 | -0.62 | 0.69 | -1.29 | -0.77 | -0.19 | -0.21 | -1.27 |
| Operating CF | (20.26M) | (21.68M) | (20.89M) | (23.44M) | (18.01M) | (14.92M) | 11.02M | (25.77M) | (9.54M) | (3.79M) | (4,497) | (13.43M) |
| Total Assets | 269.30M | 287.50M | 309.00M | 328.45M | 344.79M | 359.17M | 210.29M | 151.06M | 91.61M | 172.61M | 9.10M | 206.54M |
| Total Debt | 145,000 | 196,000 | 244,000 | 290,000 | 333,000 | 376,000 | 415,000 | 634,000 | 489,000 | 1.27M | 504,000 | 3.10M |
| Cash & Equiv | 31.42M | 35.33M | 30.51M | 35.01M | 70.15M | 98.29M | 140.73M | 67.08M | 87.09M | 24.22M | 8.26M | 18.47M |
| Book Value | 259.19M | 279.86M | 300.05M | 321.07M | 338.28M | 354.14M | 205.04M | 142.87M | (42.53M) | 161.73M | (19.73M) | 194.87M |
| Return on Equity | -0.09 | -0.08 | -0.07 | -0.06 | -0.05 | -0.04 | -0.06 | -0.05 | N/A | -0.05 | N/A | -0.00 |
TRML News
No news available for TRML.